P3H3: A Promising Drug Target and Biomarker for Prolyl 3-Hydroxylase 3

Target Name: P3H3

NCBI ID: G10536

P3H3

P3H3: A Promising Drug Target and Biomarker for Prolyl 3-Hydroxylase 3

Prolyl 3-hydroxylase 3 (P3H3) is a protein that plays a crucial role in the regulation of protein homeostasis and cell signaling pathways. The defective P3H3 gene has been implicated in various diseases, including cancer, neurodegenerative disorders, and systemic inflammatory responses. Therefore, targeting P3H3 has the potential to offer new therapeutic approaches for a variety of diseases.

P3H3: A Drug Target

P3H3 has been identified as a potential drug target due to its involvement in various cellular processes that are associated with its dysfunction. One of the key functions of P3H3 is the regulation of protein homeostasis, which is critical for maintaining cellular homeostasis and the stability of cellular structures. In addition, P3H3 is involved in the regulation of cell signaling pathways, including the NF-kappa pathway, which plays a crucial role in cell growth, differentiation, and survival.

Furthermore, P3H3 has been shown to be involved in the regulation of inflammation and immune responses. In fact, several studies have shown that P3H3-deficient mice have increased inflammatory responses and increased infiltration of immune cells in various tissues. Therefore, targeting P3H3 may be a promising approach for the treatment of inflammatory diseases.

P3H3 as a Biomarker

P3H3 has also been used as a biomarker for various diseases, including cancer, neurodegenerative disorders, and systemic inflammatory responses. In cancer, P3H3 has been shown to be involved in the regulation of cell cycle progression, DNA replication, and apoptosis. Therefore, targeting P3H3 may be a promising approach for the treatment of various cancers.

In neurodegenerative disorders, P3H3 has been shown to be involved in the regulation of protein homeostasis and the regulation of neurotransmitter release. Therefore, targeting P3H3 may be a promising approach for the treatment of neurodegenerative disorders.

In addition, P3H3 has been shown to be involved in the regulation of systemic inflammatory responses. Therefore, targeting P3H3 may be a promising approach for the treatment of systemic inflammatory responses.

Conclusion

In conclusion, P3H3 is a protein that plays a crucial role in the regulation of protein homeostasis and cell signaling pathways. The defective P3H3 gene has been implicated in various diseases, including cancer, neurodegenerative disorders, and systemic inflammatory responses. Therefore, targeting P3H3 has the potential to offer new therapeutic approaches for a variety of diseases.

Protein Name: Prolyl 3-hydroxylase 3

Functions: Part of a complex composed of PLOD1, P3H3 and P3H4 that catalyzes hydroxylation of lysine residues in collagen alpha chains and is required for normal assembly and cross-linkling of collagen fibrils. Required for normal hydroxylation of lysine residues in type I collagen chains in skin, bone, tendon, aorta and cornea. Required for normal skin stability via its role in hydroxylation of lysine residues in collagen alpha chains and in collagen fibril assembly. Apparently not required for normal prolyl 3-hydroxylation on collagen chains, possibly because it functions redundantly with other prolyl 3-hydroxylases

The "P3H3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about P3H3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets